Currently accepted screening protocols for patients at risk for developing HCC include tandem AFP and ultrasound exams every 6 months, a protocol that was derived from a prospective trial demonstrating a survival benefit in patients with hepatitis B infection and further supported by several cohort studies and meta-analyses [10,13,15,16,17,43]. The gene discussed is AFP; the disease is hepatocellular carcinoma.